YL-13027 with Gemcitabine and Nab-Paclitaxel for the Treatment of Patients with Refractory Metastatic Pancreatic Adenocarcinoma

Inclusion Criteria

• Age ≥ 18 years
• Ability to understand and the willingness to sign a written informed consent document
• Ability to comply with the study protocol, in the investigator’s judgment
• Patients with histologically confirmed metastatic pancreatic adenocarcinoma
• Refractory to one prior line of therapy in the metastatic setting. Patients are also eligible if they finished adjuvant/neoadjuvant therapy in the last 6 months and had disease recurrence
• Measurable disease with at least one lesion amenable to response assessment per the Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
• Eastern Cooperative Oncology Group performance status of 0 or 1
• Hemoglobin ≥ 8.0 g/dL
• Absolute neutrophil count ≥ 1500/mm^3
• Platelets ≥ 100,000/mm^3
• Total bilirubin ≤ 1.5 × upper limit of normal (ULN) or direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 × ULN
• Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5 × institutional ULN or ≤ 5 × ULN for patients with liver metastases
• Measured or calculated creatinine clearance (CrCl) (CrCl; Cockcroft-Gault) ≥ 50 mL/min/1.73 m^2. NOTE: For patients determined to be overweight or obese, actual body weight will be used to estimate CrCl
• For patients not receiving therapeutic anticoagulation: international normalized ratio or activated partial thromboplastin time ≤ 1.5 × ULN. For patients receiving therapeutic anticoagulation: stable anticoagulant regimen for at least 2 weeks before study entry
• Albumin ≥ 3 g/dL
• Patients must have adequate washout from prior therapy at the time of study treatment initiation: ≥ 4 weeks from major surgery (excluding biopsy; NOTE: If a patient received major surgery, she/he must have recovered adequately from the toxicity and/or complications from the intervention prior to study treatment initiation); and ≥ 2 weeks or 5 half-lives (whichever is shorter) from prior therapy
• Women of childbearing potential (WOCBP) must agree to use a highly effective method of contraception from the screening visit until 6 months after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
• Male patients of childbearing potential must agree to use a highly effective method of contraception and refrain from donating sperm from the screening visit until 3 months after the last dose of study treatment
• WOCBP must have a negative serum pregnancy test result within 72 hours prior to study treatment initiation
• Patients with secondary malignancies are eligible if the malignancy does not have the potential to interfere with the safety or efficacy assessment of the study treatment. In addition, patients receiving hormonal therapy are eligible if the hormonal therapy does not interfere with the study treatment

Exclusion Criteria

• Prior therapy with a TGF-B pathway-targeted agent
• Prior treatment with gemcitabine, nab-paclitaxel, or the combination of gemcitabine and nab-paclitaxel
• Unresolved toxicities from prior therapy (defined as having not resolved to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v. 5.0 grade ≤ 1 or baseline) or any other toxicity that is deemed irreversible by the investigator. Exceptions include endocrinopathies from prior therapy or disease and successfully treated (such as hypothyroidism, diabetes mellitus), alopecia, vitiligo, and grade ≤ 2 peripheral neuropathy
• Known symptomatic brain metastases or primary central nervous system (CNS) malignancy. Patients who have stable symptoms and are requiring steroids of 4 mg/day dexamethasone equivalent or less for 2 weeks prior to enrollment are permitted
• Live vaccines within 30 days prior to study treatment initiation
• Human immunodeficiency virus (HIV) infection with a current history of acquired immunodeficiency syndrome-defining illness or HIV infection with CD4+ T cell count < 350 cells/µL and HIV viral load more than 400 copies/µL
• Patients with active viral (any etiology) hepatitis are excluded. However, patients with serologic evidence of chronic hepatitis B virus (HBV) infection (positive hepatitis B surface antigen test and a positive hepatitis B core antibody test) who have a viral load below the limit quantification (HBV deoxyribonucleic acid [DNA] titer <1000 cps/mL or 200 IU/mL) and are not currently on viral suppressive therapy may be eligible and should be discussed with the principal investigators (PIs) and Investigation New Drug (IND) Sponsor. The addition of HBV suppressive medication (i.e., entecavir) should be considered during the period of study treatment. Patients with a history of hepatitis C virus infection who have completed curative antiviral treatment and have a viral load below the limit of quantitation may be eligible and should be discussed with the PIs and Investigational New Drug (IND) Sponsor
• Any of the following cardiac criteria experienced currently or within 6 months prior to enrollment: * Congestive heart failure (New York Heart Association Functional Classification of ≥ Class 2) * Acute coronary syndrome * Clinically significant cardiac arrhythmia
• Mean Fridericia's corrected QT interval (QTcF) > 470 ms at screening
• Left ventricular ejection fraction < 50% or the lower limit of normal (per institutional standard) at screening
• Use of strong CYP3A inhibitors or inducers are prohibited within 14 days or 5 halflives, whichever is longer, prior to study treatment initiation and during the study treatment
• Evidence of severe or uncontrolled systemic comorbidities (e.g., active bleeding diatheses or active infection), as determined by the investigator
• Patients who are pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the screening visit through 3 months after the last dose of study treatment
• Any condition that impairs a patient’s ability to swallow whole pills or presence of active gastrointestinal (GI) disease or other condition that will significantly interfere with the absorption, distribution, metabolism, or excretion of YL-13027, as determined by the investigator
• Any known psychiatric, substance abuse, or other disorder that would interfere with cooperation with the requirements of the study, in the opinion of the investigator
• Patients who are receiving any other investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drugs